Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 23, Issue 27, 2005, Pages 6664-6673

  Divers, Stephen G ^a   Spencer, Sharon A ^a   Carey, Delicia ^a   Busby, Elizabeth M ^a   Hyatt, Mark D ^a   Robert, Francisco ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSIMETRY; DRUG TOLERABILITY; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RASH; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; ADJUVANT THERAPY; CANCER INVASION; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROBABILITY; REMISSION; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PACLITAXEL; PROBABILITY; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 27244456183     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.519     Document Type: Article

References (48)

1. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909, 1995
2. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996
3. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198-205, 1995
4. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991
5. Gordon GS, Vokes EE: Chemoradiation for locally advanced, unresectable NSCLC: New standard of care, emerging strategies. Oncology (Williston Park) 13:1075-1088; discussion 1088, 1091-1094, 1999
6. Albain KS, Crowley JJ, Turrisi AT III, et al: Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20: 3454-3460, 2002
7. Choy H, Akerley W, Safran H, et al: Multi-institutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16:3316-3322, 1998
8. Curran W, Scott C, Langer C: Phase III comparison of sequential versus concurrent Chemoradiation for patients with unresectable stage III non-small-cell lung cancer: Report of Radiation Therapy Oncology Group 9410. Lung Cancer 29:93, 2000 (suppl 1; abstr 303)
9. Blackstock AW, Lesser G, Tucker D, et al: Twice weekly gemcitabine and concurrent thoracic radiotherapy: A phase I/II study in patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 19:470, 2000 (abstr 1846)
10. Chen Y, Pandya K, Keng PC, et al: Phase I/II clinical study of pulsed paclitaxel radiosensitization for thoracic malignancy: A therapeutic approach on the basis of preclinical research of human cancer cell lines. Clin Cancer Res 9:969-975, 2003
11. Choy H, Rodriguez FF, Koester S, et al: Investigation of Taxol as a potential radiation sensitizer. Cancer 71:3774-3778, 1993
12. Choy H, Safran H, Akerley W, et al: Phase Il trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Clin Cancer Res 4:1931-1936, 1998
13. Natale RB: Experience with new chemotherapeutic agents in non-small-cell lung cancer. Chest 113:325-395, 1998 (suppl 1)
14. Peters GJ, Ackland SP: New antimetabolites in preclinical and clinical development. Expert Opin Investig Drugs 5:637-679, 1996
15. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 332:1004-1014, 1995 [Erratum: N Engl J Med 333:75, 1995]
16. Shewach DS, Lawrence TS: Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol 23:65-71, 1996 (suppl 10)
17. Latz D, Fleckenstein K, Eble M, et al: Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 41:875-882, 1998
18. Heinemann V, Xu YZ, Chubb S, et al: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38:567-572, 1990
19. Shewach DS, Hahn TM, Chang E, et al: Metabolism of 2′,2′- difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54:3218-3223, 1994
20. Milas L, Hunter NR, Kurdoglu B, et al: Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol 35:297-303, 1995
21. Milross CG, Mason KA, Hunter NR, et al: Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88:1308-1314, 1996
22. Sinclair WK, Morton RA: X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29:450-474, 1996
23. Kroep JR, Giaccone G, Voorn DA, et al: Gemcitabine and paclitaxel: Pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 17:2190-2197, 1999
24. Crino L, Scagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 15:297-303, 1997
25. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111:1710-1717, 1997
26. Cancer Therapy Evaluation Program: Common toxicity criteria, version 2. Bethesda, MD, National Cancer Institute, 1998. Available at: https://webapps.ctep.nci.nih.gov/ctcv2/plsql/ ctc000w$.startup.
27. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
28. Lee ET: Statistical Methods for Survival Data Analysis. New York, NY, John Wiley and Sons, 1992
29. SAS Institute, Inc: SAS/STAT User's Guide (4th ed). Version 9. Cary, NC, SAS Institute Inc. 2002
30. Vokes EE, Gregor A, Turrisi AT: Gemcitabine and radiation therapy for non-small-cell lung cancer. Semin Oncol 25:66-69, 1998 (suppl 9)
31. Vokes EE, Leopold KA, Herndon JE, et al: A CALGB randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Inc CT) and concomitant chemoradiotherapy (XRT) in stage IIIB non-small-cell lung cancer (NSCLC): Feasibility data (CALGB study 9431). Proc Am Soc Clin Oncol 16:455, 1997 (abstr 1636)
32. Vokes EE, Herndon JE II, Crawford J, et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20:4191-4198, 2002
33. Gaspar L, Gandara D, Chansky K, et al: Consolidation docetaxel following concurrent chemoradiotherapy in pathologic IIIB non-small-cell lung cancer (SWOG 9504): Patterns of failure and updated survival. Proc Am Soc Clin Oncol 20:315,2001 (abstr 1255)
34. van Putten JW, Price A, van der Leest AH, et al: A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small-cell lung cancer. Clin Cancer Res 9:2472-2477, 2003
35. Trodella L, Granone P, Valente S, et al: Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol 20:804-810, 2002
36. Fosella FV, Zinner RG, Komaki R, et al: Gemcitabine (G) with concurrent chest radiation (XRT) followed by consolidation chemotherapy with gemcitabine plus cisplatin (CDDP): A phase I trial for patients with stage III non-small-cell lung cancer. Proc Am Soc Clin Oncol 20:312, 2001 (abstr 1243)
37. Blackstock AW, Lesser GJ, Fletcher-Steede J, et al: Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 51: 1281-1289, 2001
38. Komaki R, Seiferheld W, Ettinger D, et al: Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: Long-term follow-up of RTOG 92-04. Int J Radiat Oncol Biol Phys 53:548-557, 2002
39. Hernando ML, Marks LB, Bentel GC, et al: Radiation-induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 51:650-659, 2001
40. Martel MK, Ten Haken RK, Hazuka MB, et al: Dose-volume histogram and 3D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys 28:575-581, 1994
41. Oetzel D, Schraube P, Hensley F, et al: Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 33:445-460, 1995
42. Graham MV, Purdy JA, Emami B, et al: Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45:323-329, 1999
43. Kwa SL, Lebesque JV, Theuws JC, et al: Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 42:1-9, 1998
44. Werner-Wasik M, Scott C, Graham ML: Interfraction interval does not affect survival of patients with non-small-cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: A multivariate analysis of 1076 RTOG patients. Int J Radiat Oncol Biol Phys 44:327-331, 1999
45. Bradley J, Deasy JO, Bentzen S, et al: Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys 58:1106-1113, 2004
46. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992
47. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
48. Natale RB: Gemcitabine-containing regimens vs. others in first-line treatment of NSCLC. Oncology (Williston Park) 18:27-31, 2004 (suppl 5)